Context and chronology

Since taking office, the secretary of the U.S. Department of Health and Human Services has used budget leverage to press multilateral partners on vaccine formulation standards, demanding a concrete plan and timetable from Gavi to eliminate thimerosal from vaccines used in low-resource settings. That demand is tied to recent U.S. decisions to withhold promised support — including, by some accounts, more than $1 billion in assistance — and follows broader agency moves that have reshaped domestic vaccine policy and funding flows.

Domestically, the administration replaced key advisory committee members and moved to narrow universal endorsements for several childhood vaccines while pausing pandemic-era grants worth roughly $11 billion that previously supported local vaccination programs; those grant actions have already spawned litigation and added to uncertainty for health departments and researchers. Separately, NIH programs and about $500 million in mRNA research funding have been curtailed, while other grants studying vaccine hesitancy were reduced, shrinking predictable funding for public-health research.

Internationally, the HHS directive to Gavi departs from the assessments of leading public-health bodies, which have not found an association between thimerosal-containing vaccines and autism. Thimerosal — an ethylmercury preservative used in some multidose vials to prevent contamination during repeated access — remains present in roughly 14% of vaccine presentations in Gavi’s portfolio, largely because multidose formats are cheaper to produce, ship and store in constrained cold chains.

If Gavi were to accelerate removal without funded alternatives at scale, countries that rely on pooled procurement and multidose vials could face higher unit costs, increased cold-chain demands, and slower campaign rollouts. Manufacturers would be pressured to reformulate products and expand single-dose production — changes that require stability testing, regulatory filings and time — potentially reducing short-term supply and raising prices.

Compounding the operational risks, an ongoing neonatal safety trial of hepatitis B vaccines in Guinea-Bissau that has received partial U.S. support is now in an uncertain phase: investigators, local regulators and sponsors are weighing whether to continue under shifting funding conditions and heightened ethical scrutiny. A pause or withdrawal of support would stall data collection needed to inform newborn immunization policy in low-resource settings and create planning gaps for local health programs that depend on steady trial pipelines.

The episode illustrates a larger pattern: donor conditionality tied to politically salient ingredient concerns can quickly convert technical standards into bargaining chips, accelerating regulatory divergence across buyer blocs. Expect procurement specifications to begin diverging within months as donors demand different formulations and timelines, which will fragment markets, complicate harmonized approvals and favor manufacturers with flexible production lines.

Politically, the administration frames these moves as a recalibration toward greater scrutiny and safety; critics see them as ideologically driven steps that weaponize procurement and risk undermining evidence-based practice. The likely near-term consequences include legal and congressional oversight actions, strained relations with other donors, and potential shortfalls in routine immunization coverage if supply and affordability are disrupted.

In sum, the U.S. strategy elevates funding leverage as a policy instrument with immediate operational effects and broader geopolitical implications: it creates space for alternative suppliers to win market share by offering stable terms, pressures manufacturers to retool production, and risks eroding the consensus-driven governance that has underpinned global immunization programs.